Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 13.61% | 9.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.31% | 9.66% | |||
| Cost of Revenue | 26.49% | -67.69% | |||
| Gross Profit | 17.99% | 21.02% | |||
| SG&A Expenses | 4.72% | 0.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.98% | -6.76% | |||
| Operating Income | 1,559.66% | 95.34% | |||
| Income Before Tax | 902.49% | 104.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 881.59% | 104.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 881.59% | 104.20% | |||
| EBIT | 1,559.66% | 95.34% | |||
| EBITDA | 1,994.62% | 96.32% | |||
| EPS Basic | 867.80% | 103.84% | |||
| Normalized Basic EPS | 886.49% | 106.94% | |||
| EPS Diluted | 747.46% | 103.84% | |||
| Normalized Diluted EPS | 888.57% | 106.57% | |||
| Average Basic Shares Outstanding | 0.61% | 10.14% | |||
| Average Diluted Shares Outstanding | 2.48% | 14.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||